UNSPSC 51144013: Fluminorex

This classification denotes an anorexiant with the molecular formula C10H9F3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LUO2Z7954T, chemically known as 2-oxazolamine, 4,5-dihydro-5-(4-(trifluoromethyl)-phenyl)- but more generally known as fluminorex, which bears US NIH Compound Identifier 24100. European Medicines Agency schedules Fluminorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07703MIG. The term FLUMINOREX is an International Non-Proprietary Name.

UNSPSC 51144013 Fluminorex is a Commodity code that encompasses naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products procured by state and local health authorities, cooperative purchasing alliances, and county health departments for community health, pharmacy benefit, and emergency response programs. State and local governments buy these products through both direct competitive procurement and cooperative purchasing arrangements, with vendors expected to supply through established pharmaceutical wholesalers and deliver to county health facilities, state pharmacy benefit programs, or authorized distribution networks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction procurement and interstate cooperative arrangements that aggregate demand across multiple states and participating municipalities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, with responses due April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; this procurement spans Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, Morris & Dickson Co., LLC). Vendors supplying under the code must comply with cGMP and Drug Supply Chain Security Act requirements, maintain specified insurance coverages, and meet state and federal pharmaceutical regulations including FDA compliance and expiration-date standards.